Literature DB >> 23307238

Delayed response and survival from NovoTTF-100A in recurrent GBM.

J Lee Villano1, Leena E Williams, Karriem S Watson, Nandini Ignatius, Marquess T Wilson, Tibor Valyi-Nagy, Edward A Michals, Herbert H Engelhard.   

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

Entities:  

Mesh:

Year:  2013        PMID: 23307238     DOI: 10.1007/s12032-012-0338-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  7 in total

1.  Long-term survival after gene therapy for a recurrent glioblastoma.

Authors:  C A Valéry; D Seilhean; O Boyer; B Marro; J-J Hauw; J-L Kemeny; C Marsault; J Philippon; D Klatzmann
Journal:  Neurology       Date:  2002-04-09       Impact factor: 9.910

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

4.  Twenty-year survival in glioblastoma: a case report and molecular profile.

Authors:  Christina Maria Sperduto; Arnab Chakravarti; Ken Aldape; Peter Burger; Gail Bender Papermaster; Paul Sperduto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

5.  Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.

Authors:  Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-06       Impact factor: 7.038

6.  Long-term survivors of glioblastoma: clinical features and molecular analysis.

Authors:  Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Yoichi Nakazato; Tomoo Inoue; Masayuki Kanamori; Teiji Tominaga
Journal:  Acta Neurochir (Wien)       Date:  2009-11       Impact factor: 2.216

7.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

  7 in total
  4 in total

1.  Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma.

Authors:  Edit Bosnyák; Geoffrey R Barger; Sharon K Michelhaugh; Natasha L Robinette; Alit Amit-Yousif; Sandeep Mittal; Csaba Juhász
Journal:  Clin Nucl Med       Date:  2018-03       Impact factor: 7.794

Review 2.  The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Authors:  Stuart H Burri; Vinai Gondi; Paul D Brown; Minesh P Mehta
Journal:  Am J Clin Oncol       Date:  2018-02       Impact factor: 2.339

3.  Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Authors:  Gregory F Guzauskas; Marc Salzberg; Bruce Cm Wang
Journal:  CNS Oncol       Date:  2018-08-20

4.  Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.

Authors:  Dongjiang Chen; Son B Le; Tarun E Hutchinson; Anda-Alexandra Calinescu; Mathew Sebastian; Dan Jin; Tianyi Liu; Ashley Ghiaseddin; Maryam Rahman; David D Tran
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.